Our global life sciences company brings diagnostic testing & drug development together.
Anticardiolipin antibodies, IgG, quantitative; anticardiolipin antibodies, IgM, quantitative
1 - 3 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
For more information, please view the literature below.
Red-top tube or gel-barrier tube
Hemolysis; lipemia; icteric specimen
Anticardiolipin antibodies are often present in individuals with the antiphospholipid antibody syndrome.1,2
ACA can often be observed during the convalescent phase of acute bacterial and viral infections and in individuals with syphilis. These infection-induced antibodies are usually transient and are not associated with an increased risk of clinical complications. In general, all patients who test positive ACA should be retested after six to eight weeks to rule out transient antibodies that are usually of no clinical significance.
Enzyme-linked immunosorbent assay (ELISA) detecting isotype-specific ACA binding to a microtiter plate coated with purified cardiolipin antigen
− Negative: <15 GPL
− Indeterminate: 15−20 GPL
− Low-medium positive: >20−80 GPL
− Positive: >80 GPL
− Negative: <13 MPL
− Indeterminate: 13−20 MPL
− Low-medium positive: >20−80 MPL
− Positive: >80 MPL
Individuals with the antiphospholipid antibody syndrome (APS) have an increased risk for stroke, myocardial infarction, venous thrombosis, thromboembolism, thrombocytopenia, and/or recurrent miscarriages. In 1999, an international consensus conference found that one criterion for the serologic diagnosis of “definite antiphospholipid syndrome” is the presence of anticardiolipin antibody of IgG and/or IgM isotype, at medium or high titer, on two or more occasions, at least 6 weeks apart.3 The presence of ACA of moderate to high titer for IgG is strongly associated with both arterial and venous thrombosis and recurrent pregnancy loss.2,4,5 The IgM isotype of ACA has also been shown to be associated with venous thrombosis.4 Other studies found that ACA of the IgA isotype at moderate to high titer can also be associated with increased risk of APS.2,6
ACA antibodies are quite common in the general population and are not always associated with APS. Studies indicate that there is a higher prevalence of IgM positives than IgG in the general population with these isotypes occurring in 9.4% and 6.5% of the population, respectively.7 The incidence of these ACA is even higher in normal pregnancy with detection rates of 17% for IgM and 10.6% for IgG.8 Many of these antibodies are transient and not associated with APS. The diagnosis of APS should not be made on the basis of a single ACA result but rather on repeated positive results obtained at least six weeks apart.1
The Venereal Disease Research Laboratory (VDRL) agglutination test that has been used for decades in the diagnosis of syphilis is based on the detection of antibodies to cardiolipin.9 The first solid-phase immunoassays for ACA were developed in the early 1980s.9 These solid-phase assays are at least 100-fold more sensitive than the classical VDRL assay and produce many more positive results. In general, ACA are considered to be more sensitive than lupus anticoagulants (LA) for the detection of APS.4 The ACA test is positive in 80% to 90% of patients with APS,10 and ACA are implicated in approximately five times more cases of APS than are LA;2 however, LA are considered to be more specific for APS than ACA.2,10 Due to the heterogeneity of antibodies associated with APS, both LA and ACA testing is recommend when APS is suspected.4,11
ACA are frequently observed in patients with other autoimmune disorders and malignancies. Individuals with ACA secondary to these other conditions are at increased risk of developing APS. A variety of therapeutic drugs can induce the production of ACA. These drug-induced antibodies may be clinically significant if they persist.2,12
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|161802||Anticardiolipin Ab, IgG/M, Qn||161812||Anticardiolipin Ab,IgG,Qn||GPL U/mL||3181-5|
|161802||Anticardiolipin Ab, IgG/M, Qn||161830||Anticardiolipin Ab,IgM,Qn||MPL U/mL||3182-3|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf